French-Belgian MedTech firm neuroClues has secured €10 million in a Series A round, elevating its total funding to €25 million. Led by Teampact Ventures, White Fund, and the EIC Fund, this capital will accelerate the European rollout of its diagnostic device. The technology uses eye-movement analysis for the early detection of neurological disorders, years before symptoms become visible.
Revolutionizing Neurological Diagnostics
Neurodegenerative diseases are a growing crisis, with conditions like Parkinson's often misdiagnosed until after irreversible brain damage occurs. Clinicians have long relied on subjective tests like "follow my finger" or costly imaging that lacks early-stage sensitivity. This diagnostic gap results in delayed treatment, impacting millions of patients and straining healthcare systems worldwide.
neuroClues addresses this challenge with a portable, CE-marked device that extracts objective biomarkers from eye movements. Within a ten-minute exam, the system uses high-speed cameras and AI to generate reproducible data for clinicians. This technology transforms a century of oculomotor research into a practical tool for everyday clinical use, providing immediate, quantifiable insights.
Validated Technology and Rapid Market Entry
After obtaining its CE certification in January 2025, neuroClues achieved remarkable commercial momentum in a matter of months. The company has already deployed over 30 devices in hospitals and private neurology practices across seven European countries. This rapid adoption is driven by strong inbound demand from clinicians who have seen the device's effectiveness firsthand.
The technology's credibility is bolstered by major clinical partnerships, including integration into cohorts at the prestigious Paris Brain Institute. Furthermore, neuroClues was selected for a mega-cohort project involving 25,000 participants to build a large-scale normative database. These collaborations provide a strong scientific foundation for the platform's continued development and widespread clinical acceptance.
Fueling European Expansion
The Series A funds are earmarked for an aggressive European commercial expansion. To spearhead this growth, the company has appointed former Medtronic executive Bart Stulens as its Chief Commercial Officer. neuroClues is now actively building its sales team and securing distributor agreements across the EMEA region to meet rising market demand.
Investor confidence in the company's strategy is high, with the round led by prominent venture funds and supported by existing shareholders. Romain Vidal of Teampact Ventures praised the company's rare ability to turn deep scientific research into a market-ready product. This strong backing validates both the technology and the company's execution capabilities in a competitive MedTech landscape.
In a novel approach to funding, neuroClues has opened a €1.5 million tranche on the LITA impact investment platform. This allows individual citizens to invest alongside institutional backers under the same terms, reflecting the company's mission-driven focus. The initiative democratizes access to MedTech investment while aligning the company with a community of impact-focused supporters.
This €10 million investment marks a pivotal milestone for neuroClues, providing the resources to scale its transformative diagnostic technology across Europe. By offering an objective, accessible solution for early detection, the company is poised to significantly improve neurological patient care. The combination of advanced technology, rapid market adoption, and strong investor backing positions neuroClues at the forefront of neurotech innovation.